Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Phase 2 Completed
24 enrolled
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Phase 2 Completed
75 enrolled 12 charts
SAMCO
Phase 2 Completed
132 enrolled
OPTIPRIME
Phase 2 Completed
118 enrolled
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
Phase 1/2 Completed
111 enrolled 22 charts
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Phase 1/2 Completed
29 enrolled 17 charts
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
Phase 1/2 Completed
177 enrolled 31 charts
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
Phase 2 Completed
74 enrolled 15 charts
VALIDATE
Completed
647 enrolled
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Phase 2 Completed
200 enrolled 23 charts
PARADIGM
Phase 3 Completed
823 enrolled 20 charts
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
Phase 1/2 Completed
22 enrolled
VOLFI
Phase 2 Completed
93 enrolled
PanaMa
Phase 2 Completed
387 enrolled
TRIPLETE
Phase 3 Completed
435 enrolled
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Phase 2 Completed
285 enrolled 31 charts
Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients
Completed
213 enrolled 30 charts
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Phase 2 Completed
203 enrolled 14 charts
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Phase 3 Completed
463 enrolled 17 charts
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Phase 3 Completed
1,183 enrolled 18 charts
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Phase 3 Completed
1,010 enrolled 22 charts
CHRONOS
Phase 2 Completed
32 enrolled
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
Phase 3 Completed
1,198 enrolled
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
Phase 2 Completed
14 enrolled
IMPROVE
Phase 2 Completed
151 enrolled
OPALO
Phase 2 Completed
20 enrolled
CaboMAb
Phase 1 Completed
29 enrolled
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Phase 2 Completed
154 enrolled 18 charts
SAPPHIRE
Phase 2 Completed
164 enrolled 29 charts
A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases
Phase 2 Completed
11 enrolled
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Phase 2 Completed
28 enrolled 11 charts
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Phase 3 Completed
1,053 enrolled 25 charts
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Phase 2 Completed
266 enrolled 17 charts
PULSE
Phase 2 Completed
78 enrolled
PIE
Phase 1/2 Completed
49 enrolled
ULTRA
Phase 2 Completed
72 enrolled
Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
Phase 2 Completed
20 enrolled 11 charts
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
Completed
3,091 enrolled 12 charts
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Phase 3 Completed
377 enrolled 20 charts
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Phase 1 Completed
28 enrolled 11 charts
STEPP
Phase 2 Completed
95 enrolled 23 charts
PRECEPT
Phase 2 Completed
116 enrolled 20 charts
Biomarker - Panitumumab Response With KRAS Wild Type MCC
Phase NA Completed
52 enrolled
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Phase 2 Completed
15 enrolled 7 charts
FRAIL
Phase 2 Completed
33 enrolled
Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients
Phase 2 Completed
78 enrolled
Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
Phase 2 Completed
68 enrolled
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Phase 1/2 Completed
53 enrolled 13 charts
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Phase 2 Completed
185 enrolled 15 charts
Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC
Phase 2 Completed
85 enrolled